复方丹参注射液联合依达拉奉治疗急性脑梗死的临床疗效及对copeptin、NT－proBNP和Hcy水平的影响

摘要

目的：探讨复方丹参注射液联合依达拉奉治疗对急性脑梗死的临床疗效。方法将130急性脑梗死患者随机分为对照组（65例）和观察组（65例），对照组给予依达拉奉注射剂治疗，观察组给予复方丹参注射液＋依达拉奉注射液联合治疗，使用NIHSS评分并结合Barthel指数评分评价疗效，采用ELISA法检测患者治疗前后血清中的copeptin，NT－proBNP和Hcy水平。结果复方丹参注射液＋依达拉奉联合治疗疗效显著优于依达拉奉单方（P＜0．01），治疗后2组患者copeptin，NT－proBNP和Hcy水平显著改善（P＜0．01），但复方丹参注射液＋依达拉奉联合治疗改善效果显著优于依达拉奉单方（P＜0．01）。结论复方丹参注射液＋依达拉奉联合治疗效果较优。%Objective To study the therapeutical effects of compound Danshen injection combined with edaravone in treatment of acute cerebral infarction.Methods 130 cases of ACI were randomly divided into two groups, control group(65 case) and observation group(65 cases), control group were administered with edaravone injection, while observation group were administered with compound Danshen injection and edaravone injection, NIHSS score and Barthel index score were used for effects evaluation, meanwhile, serous levels of copeptin, NT-proBNP and Hcy were measured by ELISA assay.Results Observation group had a better effect on ACI care, compared with control group (P<0.01), and serum levels of copeptin,NT-proBNP and Hcy significantly improved both in the two groups ( P <0.01 ) , while, observation group had a better effects ( P <0.01 ) . Conclusion Combination therapy of compound Danshen injection and edaravone has a fabulous effect on ACI care.